This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 2 of 2
Next »

Alexza Pharma: Run-Up Trade Into December's Approval Decisions

By Mark Messier

Alexza expects US and European regulators to announce approval decisions in December.

08:03AM 11/20/12

Celsion: Run-Up Trade Into Thermodox Results

By Mark Messier

Traders are already bidding up shares of Celsion in anticipation of pivotal trial results.

07:01AM 11/14/12

Short Trade: Supernus IPO Lock-Up

By Mark Messier

Supernus share should fall now that 10 million shares under lock-up can now be sold.

07:00AM 10/31/12

How to Prep for the Inevitable Bursting of the Biotech Stock Bubble

By Mark Messier

Traders need to be less cocky and more prepared for when stocks fall.

07:00AM 10/17/12

AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades

By Mark Messier

The biotech bull market has created a new category of swing trade catalysts.

07:05AM 10/09/12

How to Trade Hemispherx Even If You Hate the Stock

By Mark Messier

Biotech swing trader Mark Messier warns to look at Hemispherx as a short-term trade, not an investment.

10:48AM 10/02/12

Zogenix: Three Shots At Run-Up Trade

By Mark Messier

Get in Zogenix early before other traders start speculating over its chronic pain drug Zohydro.

08:00AM 09/26/12

Acadia Pharma, Sarepta Therapeutics: How to Trade Into Trial Results

By Mark Messier

Biotech trader Mark Messier explains how to position trades ahead of two important biotech clinical trials.

07:31AM 09/19/12

Dynavax: The BioRunUp Trade Into An FDA Panel

By Mark Messier

Biotech trader Mark Messier explains how to swing trade Dynavax into a Nov. 14 FDA advisory panel.

11:34AM 09/11/12

Page 2 of 2
Next »

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs